article thumbnail

The Benefits of Integrated CDMO Services: Streamlining Drug Development and Manufacturing

Drug Patent Watch

” – Patheon “By possessing a deeper understanding of the regulations that apply to each step of the development and manufacturing journey, embedded CDMOs can often anticipate questions and issues that might arise and help avoid costly delays.” 2019, March 14). Retrieved from [link] Pfizer CentreOne.

article thumbnail

CDMO Selection: The Ultimate Checklist

Drug Patent Watch

Pharmaceutical companies should evaluate a CDMOs compliance with industry standards and regulations, ensuring that they have a robust quality assurance system in place. 2019, March 6). Regulatory Compliance and Quality Assurance Regulatory compliance and quality assurance are essential aspects of CDMO selection. Contract Pharma.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The future of CNS drug development: signs of real progress

Drug Target Review

Developers and sponsors working on biologically derived therapies in the US can utilise the Regenerative Medicine Advanced Therapy (RMAT) designation, which regulators grant to promising regenerative therapies. Epub 2019 Nov 29. The blood–brain barrier: Structure, regulation and drug delivery. Adv Drug Deliv Rev. 2019.11.009.

article thumbnail

Boosters and Biologics: Is Space-Based Biomanufacturing Real?

LifeSciVC

Regulators may reasonably ask is a drug crystallized in orbit the same as if made on Earth? Regardless, dedicated bioproduction facilities will be essential infrastructure, but the development, validation, production, and deployment of such systems is not guaranteed. Regulatory : there is no regulatory framework for products made in space.

Science 96
article thumbnail

Rilzabrutinib Cuts Flares in IgG4-Related Disease; Fast Track Granted in US

The Pharma Data

All participants met the ACR/EULAR 2019 diagnostic criteria for IgG4-RD and had a minimum IgG4-RD Responder Index (RI) score of 2 or greater at baseline. Importantly, most participants presented with active disease in at least one organ , with the exception of the lymph nodes.

Disease 40
article thumbnail

Highlights From the 2025 American Society for Mass Spectrometry Conference | By Jean-François Larocque and Benjamin Charron

Alta Sciences

ABOUT THE AUTHORS Jean-François Larocque, Principal Scientist, Mass Spectrometry, Altasciences Jean-François joined Altasciences in 2019 and is based in the Greater Montréal Area (Canada). As a scientist, he is responsible for assay development and supporting regulated scientists for a smooth transition of the methods to a validated state.

article thumbnail

Navigating Regulatory Hurdles in Drug Development

DrugBank

Drug development is a complex and highly regulated process. While these regulations protect public health, they also introduce significant challenges for pharmaceutical researchers. This means pharmaceutical companies must remain vigilant and adaptable to comply with evolving regulations. Regulatory agencies, such as the U.S.